Pfizer (NYSE:PFE) Receives "Buy" Rating from Guggenheim

Pfizer (NYSE:PFE - Get Free Report)'s stock had its "buy" rating reiterated by Guggenheim in a report released on Monday,Benzinga reports. They presently have a $33.00 price target on the biopharmaceutical company's stock. Guggenheim's price target suggests a potential upside of 28.33% from the company's current price.

Several other research analysts have also recently weighed in on PFE. Citigroup decreased their price target on Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. Bank of America reissued a "neutral" rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Truist Financial dropped their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, December 18th. Wolfe Research started coverage on shares of Pfizer in a report on Friday, November 15th. They set an "underperform" rating and a $25.00 price objective for the company. Finally, UBS Group dropped their target price on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $31.92.

Pfizer Trading Up 1.0 %

PFE stock traded up $0.25 during midday trading on Monday, hitting $25.72. The company had a trading volume of 20,154,082 shares, compared to its average volume of 37,790,719. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer has a 52 week low of $24.48 and a 52 week high of $31.54. The stock has a market cap of $145.73 billion, a price-to-earnings ratio of 18.25, a PEG ratio of 0.64 and a beta of 0.64. The stock's 50 day moving average price is $26.28 and its 200 day moving average price is $27.63.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter in the prior year, the company posted $0.10 EPS. The firm's revenue for the quarter was up 24.7% compared to the same quarter last year. As a group, equities research analysts expect that Pfizer will post 2.95 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pfizer

Large investors have recently added to or reduced their stakes in the company. Rockefeller Capital Management L.P. raised its position in shares of Pfizer by 2.2% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,665,404 shares of the biopharmaceutical company's stock valued at $44,189,000 after purchasing an additional 35,315 shares during the period. NFP Retirement Inc. increased its stake in Pfizer by 8.4% in the 4th quarter. NFP Retirement Inc. now owns 7,920 shares of the biopharmaceutical company's stock worth $210,000 after buying an additional 614 shares in the last quarter. Inlight Wealth Management LLC purchased a new stake in Pfizer in the 4th quarter worth $3,236,000. Quinn Opportunity Partners LLC lifted its position in shares of Pfizer by 23.1% in the fourth quarter. Quinn Opportunity Partners LLC now owns 557,728 shares of the biopharmaceutical company's stock valued at $14,797,000 after acquiring an additional 104,818 shares in the last quarter. Finally, Heritage Trust Co bought a new position in shares of Pfizer in the fourth quarter worth about $2,261,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.